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Background: Despite all benefit provided by established therapies prognosis of gastric cancer remains poor.
Targeted inhibition of platelet derived growth factor receptor (PDGFR) by imatinib may influence tumor growth
and amplify chemotherapeutic effects.
Methods: This phase I study evaluated dose limiting toxicity (DLT) of imatinib combinated with chemotherapy
according to a 3-patient cohort dose-escalating design. Thirty-five patients received cisplatin (60 mg/m2 d1 q 3w)/
capecitabine (1250 mg/m2 bid d1-14 q 21) or cisplatin (50 mg/m2 d1 q 2w)/ 5-fluoruracil (2 g/m2 d1, q 1w).
Imatinib was started d - 4 with dose escalation from 300 to 700 mg QD in 100 mg steps.
Results: At imatinib dose level 1 (300mg) one DLT was observed, three more patients were enrolled without
further DLT. At dose level 5 (700 mg) two gastric perforations occurred, so 600 mg imatinib emerged as the
maximum tolerated dose. Major grade 3/4 toxicities were nausea (6%), anemia (6%) and fatigue (3%). Response
evaluation revealed partial response in 27% and stable disease in 43% of the assessable patients.
Conclusions: Combination of imatinib and chemotherapy is well tolerated. Response rates were not superior to
those of standard therapy. Further investigations of a larger group of patients are required to confirm the
amplification of chemotherapy effects by imatinib.
Trial registration: European Clinical Trials Database: Eudra-CT2006-005792-17 and Clinical Trials Database:
NCT00601510
Keywords: Imatinib, PDGF, Gastric cancer, ChemotherapyBackground
Evidence for benefit of chemotherapy in patients with
advanced gastroesophageal and gastric cancer is increas-
ing. Several studies demonstrated improved overall sur-
vival and quality of life for chemotherapy compared to
best supportive care [1-3]. Also, a variety of clinical trials
showed superiority of combination therapy over single-
agent therapy [4]. But resection is still the only chance
for cure and most patients present with advanced dis-
ease initially. Despite all positive effects of pre- and* Correspondence: Matthias.Ebert@umm.de
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reproduction in any medium, provided the orperioperative chemotherapy, relapse rates of gastric can-
cer are high. Integration of targeted therapies into novel
treatment strategies may provide an additional benefit,
but actually experience in this field is limited to just a
few trials [5].
Receptor tyrosine kinases (RTK) represent an interest-
ing molecular target due to their pivotal role in signal
transduction and malignant transformation. They have
an essential function in the regulation of cell growth,
development, metastasis and apoptosis [6-8]. The platelet-
derived growth factor receptors (PDGFR) as a transmem-
brane RTK subgroup are expressed in various human
tumors, including ovarian, gastric and colorectal cancer
[9-12]. The platelet-derived growth factors (PDGF) pro-
teins constitute several isoforms: PDGF-AA, PDGF-BB,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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α-receptor binds all variants except PDGF-DD, whereas
the β-receptor binds only PDGF-BB. PDGFs are potent
chemotactic and mitogenic growth factors for fibro-
blasts, endothelial cells and smooth muscle cells. They
stimulate the growth of stromal tissue in malignant
tumors by activating so called carcinoma-associated
fibroblasts (CAFs) [14]. Besides they have been found
to promote angiogenesis [15], to recruit pericytes [16]
and to affect interstitial fluid pressure (IFP) being
responsible for the transvascular transport of che-
motherapeutics [17]. Therefore inhibition of the PDGF
RTK- signaling promises interesting effects on tumor
growth.
Imatinib (Glivec W) is a highly selective inhibitor of the
RTK family comprising Abl, the Bcr-Abl fusion protein
found in most cases of chronic myeloid leukemia
(CML), PDGFR- α and -β, and the product of the c-kit
proto-oncogene (KIT). In patients with CML and in
patients with c-kit-positive gastrointestinal stroma
tumors imatinib therapy is a well tolerated and effective
treatment strategy. Several trials demonstrated the piv-
otal role of PDGF-B and PDGFR-β expression for
human gastric carcinoma as well in mouse models [8] as
in gastric carcinoma cell lines and surgical specimens
[18]. The authors presume promising effects by the
blockade of PDGFR signaling pathways. According to
this, our own preclinical data demonstrate gastric cancer
cells expressing PDGFR as well as c-kit and their growth
being evidently inhibited by imatinib. Further, previous
studies showed imatinib to amplify the effects of cis-
platin [7] and 5-fluoruracil and leucovorin [19] in certain
cancer cells. Therefore blocking the PDGF mediated sig-
nal transduction pathway may enhance chemotherapeu-
tic effects in the treatment of gastric cancer. In mouse
models especially combination with high-dose imatinib
revealed significant potency [8].
This phase I study was performed to evaluate safety and
dose limiting toxicity (DLT) of imatinib in combination
with chemotherapy in patients with advanced esophageal
and gastric adenocarcinoma. Besides docetaxel-based regi-
mens and trastuzumab containing therapies for HER2-
positive cancer, 5-fluoruracil (FU)-based combinations
with cisplatin or oxaliplatin are regarded the chemothera-
peutic standard. The PLF- regimen with 5-FU (F), leucov-
orin (L) and cisplatin (P) is one of the most common
regimes [3,20]. However, 5-FU is replaced more often by
its prodrug Capecitabine, since recent studies proved non-
inferiority of capecitabine compared to infusional FU
and similar toxicities except diarrhea and hand-foot syn-
drome [21-23]. Therefore both fluoropyrimidines were
combined with cisplatin and imatinib in order to assess
the toxicity of this therapy in gastric and esophageal
adenocarcinoma patients.Methods
Preclinical analysis
Preliminary investigations of the PDGFR– and c-kit (CD
117) - expression in gastric cancer cells were performed
on tissue specimens of 57 patients with gastric cancer
(specimens were retrieved from the archive of the de-
partment of pathology, Kiel). The average age of patients
was 66 years (range 26 to 84), 31 male and 26 female
subjects (m: f = 1,2 :1). Gastric cancer was classified
according to Laurén into diffuse type (27 patients) and
intestinal (30 patients). Paraffin embedded specimens
were cut at 3 μm serial sections and placed on glass
slides. They were deparaffinized and stained using
hematoxylin and eosin. After pretreatment with EDTA
immunostaining was performed with a monoclonal anti-
body against PDGFR-β (R&D Systems, dilution 1:20) and
a polyclonal antibody against CD117 (WAK-Chemie,
Berlin, Germany, dilution 1:2000) as primary antibody.
Biotinylated anti-mouse IgG/ anti-rabbit IgG (Vector
Laboratories, dilution 1:200) was administered as sec-
ondary antibody. Immunoreactions were visualized with
the avidin biotin complex method, applying a Vectastain
ABC alkaline phosphatase kit. The biotinylated second-
ary antibody, the avidin-horse-radish-peroxidase conju-
gate, and the basic DAB solution were applied, according
to the manufacturer's instructions. All specimens were
counterstained with hematoxylin. Primary antibodies
were omitted for negative controls.
Patient eligibility
This multicenter open label phase I study was approved
by the ethics committees of the participating centers and
registered with the European Clinical Trials Database
(Eudra-CT 2006-005792-17) and the Clinical Trials
Database (NCT 00601510). All enrolled patients gave
their written informed consent. Inclusion criteria were
defined: histologically confirmed advanced esophageal or
gastric adenocarcinoma, presence of at least one mea-
sureable lesion according to RECIST criteria, adequate
hematopoietic, hepatic and renal function – defined as:
white blood cell (WBC) count ≥ 3000/μl, absolute neu-
trophil count (ANC) ≥ 2000/μl, platelets ≥ 100000/μl,
hemoglobin level ≥ 9.0 g/dl, total bilirubin < 2 times the
upper limit of normal (ULN) , SGOT and SGPT < 2.5
times the UNL (or < 5 x ULN if hepatic metastases are
present), glomerular filtration rate (GFR) ≥ 60ml/min,
Eastern Cooperative Oncology Group (ECOG) perform-
ance status ≤ 2. Exclusion criteria were: Any other active
primary malignancy, severe uncontrolled medical illness,
cardiac insufficiency (New York Heart Association III–
IV), chronic liver diseases, known brain metastases,
known diagnosis of human immunodeficiency virus
(HIV) infection, known dihydropyrimidine dehydrogen-
ase-deficiency, concurrent use of Sorivudin or related
Mayr et al. BMC Cancer 2012, 12:587 Page 3 of 7
http://www.biomedcentral.com/1471-2407/12/587substances, previous radiotherapy to ≥ 25% of the bone
marrow or major surgery within 2 weeks before study
entry.
Treatment design
This trial was designed to assess safety and tolerability of
imatinib combined with chemotherapy in order to deter-
mine the maximum tolerable dose (MTD). Patients
received imatinib and chemotherapy with cisplatin and
capecitabine or cisplatin and 5-FU/Leucovorin according
to the treatment regimes presented in Table 1. Therapy
regimen was chosen according to the patients prefer-
ences for infusional 5-FU or orally administered capeci-
tabine. Imatinib was administered orally as a single dose
starting on day −4 and continued throughout the
complete treatment cycle. The therapy regimen related
to a dose escalation design with cohorts of three to six
patients according to the Fibonacci scheme. Imatinib
dosage started at 300 mg and the maximum dose level
to reach was 800 mg. If none of three patients had dose
limiting toxicity (DLT), dose was escalated in 100 mg
steps cohort-to-cohort. If one of three patients experi-
enced a DLT, three more patients were included in this
cohort. Further dose escalation was only permitted if not
more than one of six had DLT. The MTD was the high-
est dose of imatinib that resulted in DLT in fewer than
one in 3 or 2 in 6 patients per cohort. Only toxicities
during the first three cycles were considered for defining
the MTD. Combination therapy continued until best re-
sponse, evidence of progressive disease, unacceptable
toxicity, death or withdrawal of patients consent. The
preliminary antitumor activity was defined as a second-
ary objective.
Toxicity and efficacy assessment
Safety and toxicity assessment was performed by regular
patient interviews, laboratory tests and physical exami-
nations. Potential dose limiting toxicities were graded
according to the National Cancer Institute Common
Toxicity Criteria (NCI-CTC VERSION 3.0). Dose limit-
ing toxicity (DLT) was defined as grade 3 neutropenia
with fever or infection; grade 4 neutropenia persisting ≥
7 days; grade 3 thrombocytopenia with bleeding or grade
4 thrombocytopenia > 7 days; any non-hematological
toxicity grade 3 or 4 except alopecia, nausea andTable 1 Chemotherapy regimens
Substance Dose (mg/m2
PLF q d 50 cisplatin 50
5-fluoruracil 2000
leucovorin 500
XP q d 22 cisplatin 60
capecitabine 1250vomiting; increase in urinary retention parameters ≥
grade 2; peripheral sensory neuropathy ≥ grade 3. Rela-
tion between study drug and toxicity was evaluated with
respect to the differences of the side effects of fluorura-
cil/leucovorin and capecitabine. Dose modifications were
conducted as follows: If a patient experienced a non-
hematological ≥ grade 2 toxicity administration of the
study drug and chemotherapy was withheld until toxicity
has resolved to ≤ grade 1. Then chemotherapy and ima-
tinib were resumed at the same daily dose. If grade 2
toxicity recurred dose of the suspected underlying drug
was reduced according to a predetermined scheme. If
the criteria for continuation of the chemotherapy were
not fulfilled after 2 weeks of dose modification or treat-
ment break the patient was withdrawn from the trial. If
hematological toxicity ≥ grade 3 occurred treatment had
to be interrupted until toxicity had resolved to ≤ grade
1. Imatinib and chemotherapy proceeded at the same
dose if toxicity resolved within two weeks. If the toxicity
≥ grade 2 persisted or recurred imatinib had to be with-
held and therapy had to be adapted referring to the
study scheme. No dose reductions were performed for ≥
grade 3 anemia.
Antitumor activity was evaluated as a function of ob-
jective tumor response. For efficacy assessment CT or
MRI scans were performed before start of study treat-
ment, after 6 weeks and thereafter every 12 weeks until
disease progression or study withdrawal from any other
cause. Responses were defined according to RECIST cri-
teria and classified according to the WHO-criteria.
Results
Expression of PDGFR and c-kit in gastric cancer
The expression and spatial distribution of PDGFR-β was
investigated by immunohistochemistry of tissue speci-
mens obtained by surgery from 20 patients. Immunos-
taining for PDGFR-β was found in each specimen.
PDGFR-β was detected in the tumor cells of 16 patients
more commonly in intestinal type [9 (100%) patients]
than in diffuse type [6 (55%) patients]. A cytoplasmic
staining of less than 10% of the tumor cells was found in
6 cases, a staining of 10-50% in three, and a staining of
greater than 50% was found in 7 tumors. Apart from
tumor cells, gastric surface epithelium expressed
PDGFR-β in 10 patients, and smooth muscle cells of the) Application Schedule
1 hr infusion d 1, 15, 29
24 hr infusion d 1, 8, 15, 22, 29,36
2 hr infusion d 1, 8, 15, 22, 29,36
1 hr infusion d 1
bid p.o. d 1 -14
Figure 2 C-kit-immunohistochemistry. Expression of CD117
in gastric cancer specimens: Intestinal type (a, b-arrowhead)
and diffuse type (d) gastric cancer specimens enclosed
CD117-immunoreactive mast cells. Occasionally was CD117
expressed by tumor cells (b) and stromal cells (c-arrowhead).
Anti-CD117, hematoxylin counterstain; Original magnifications: x400.
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patients. Interestingly, PDGFR-β was expressed also
from moderately to strongly by myocytes of vessel walls
in 19 patients (Figure 1).
To determine the expression and spatial distribution
of CD117 immunohistochemical analysis was carried out
in neoplastic and non-neoplastic tissue specimens from
37 patients. CD117 immunoreactivity was present in
each specimen, it was found in every case in mast cells
and in cells of Cajal. Tumor cells stained for CD117 in 4
(11%) patients. In 3 cases less than 10% of the tumor
cells expressed CD117 and in a single case 10-50% of
the tumor cells. In 3 tumor specimens a weak expression
of CD117 was found in few cells of the tumor stroma
(Figure 2).
Patients
From March 2008 to November 2010 39 patients were
enrolled in the study. Two patients dropped out due to a
rapid worsening of their general condition before start-
ing treatment. One patient decided to have chemoembo-
lisation of liver metastases and one patient withdrew
consent for personal reasons before first dosage. Thus
35 patients were eligible for the study and assigned to 5
treatment cohorts. The median age was 61 years (range,
39–76 years), and 21 (60%) of patients had an ECOG PS
of 0. For 15 (43%) patients without evidence for distant
metastases therapy was started as neoadjuvant treat-
ment. The remaining 20 (57%) patients received pallia-
tive chemotherapy intent due to distant metastases, an
unresectable primary tumor or cancer manifestation as aFigure 1 PDGF-immunohistochemistry. Expression of PDGFR-β in
gastric cancer specimens: Intestinal type (a) gastric cancer expressed
more commonly PDGFR-β, while diffuse type (b) often showed no
expression. Note strong expression of PDGFR-β in the surface
epithelium (b). Interestingly, PDGFR-β, was also found in myocytes
of tumor blood vessel (c, d). Anti- PDGFR-β, hematoxylin
counterstain; Original magnifications: x400 (a), x200 (b, d).relapse of malignancy. One patient initially considered
unresectable underwent surgery after notably shrinkage
of a paraesophageal lymph node metastasis. Thirty-five
patients were assessable for toxicity and safety analysis,
25 (71%) patients were assessable for efficacy. Baseline
characteristics are summarized in Table 2.
Safety, tolerability and MTD
The 35 eligible patients were treated in 5 cohorts at 5
dosage levels of imatinib. At imatinib dose level 1
(300mg) within 3 patients one DLT was observed con-
sisting of immediate gastrointestinal intolerance with
grade 3 nausea and anorexia. According to the 3-
patient-cohort study design three more patients were
included in this dosage group and no further DLT
emerged. The imatinib dose was escalated via three
more cohorts without any additional DLT encountered.
At dose level 5 (700mg imatinib) two gastric perfora-
tions occurred. The first patient (73 year old, male) with
gastric cancer experienced this severe adverse event 4
weeks after start of therapy. Imatinib intake had lasted
only 7 days until this time point because recurrent mod-
erate toxicities (nausea, diarrhea) were observed and
demanded – together with the worsening general
condition- repeated hospitalization and treatment
breaks. After appearance of the first symptoms gastric
perforation was diagnosed immediately and emergency
surgery was performed. Initially, the patient recovered as
expected after surgery but then several cerebral seizures
occurred. Computed tomography scan revealed exten-
sive cerebral metastases. It was decided not to continue
with anticancer therapy in view of the fatal prognosis
Table 2 Patient baseline characteristics (n = 35)
Characteristics N = 35
Median age (range), years 61 (39–76)









well / moderately differentiated 6











ECOG, Eastern Cooperative Oncology Group.
PS, Performance status.
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palliative care. The second case of gastric perforation
developed in a 55 year old female gastric cancer patient
7 days after start of treatment with 7 days of imatinib in-
take completed. Emergency surgery of this patient was
performed in a local hospital and the patient recovered
without sequelae.
Regarding these dose-limiting events imatinib dose
level 4 (600 mg) was defined as the maximum tolerated
dose (Table 3). All additionally enrolled patients were
assigned to this dose level until the number of patients
evaluable for response analysis was reached.
Median treatment duration was 14 weeks (range 1–
24). Most of the adverse events were grade 1 (65%) and
2 (21%). Major grade 3 (14%) and grade 4 (1%) toxicities
were nausea (6%), anemia (6%), fatigue (3%) and upperTable 3 Dose limiting toxic effects by dose level
Dose level (mg) n Dose limiting toxicity (n)




700 2 gastric perforation (2)GI hemorrhage (3%). There was no difference depending
on the chosen chemotherapeutic regimen (fluoruracil or
capecitabine). Dosage reduction of chemotherapy was
necessary in 7% of the administered cycles without not-
able correlation to the dose level of imatinib. No patient
died as a consequence of treatment related toxicity.
Toxicities are presented in Table 4.
Activity
First efficacy assessment was performed 6 weeks after
start of study treatment. According to the study protocol
only patients who received imatinib for at least three
weeks are assessable for efficacy, leaving 25 out of 35
eligible patients for analysis. Response evaluation at
6 weeks revealed partial response (PR) in 27%, stable dis-
ease (SD) in 43% and progressive disease (PD) in 13% of
the assessable patients. For the second response evalu-
ation 12 weeks later 11 patients were assessable. The
majority of those achieved stable disease (55%), partial
response was affirmed in 27% and 18% had progressive
disease. At both evaluations there was no difference in
activity concerning cancer localisation (esophageal or
gastric cancer) or chosen chemotherapeutic schedule
(cisplatin/capecitabine or cisplatin/5-fluoruracil/leucov-
orin). For 13 (37%) patients who abandoned study treat-
ment due to progressive disease median time to
progression was 19 weeks (range 6–57). The median
overall survival for these patients was 59 weeks (range
22–103).
Discussion
Improvement of the therapeutic options for patients
with advanced esophageal and gastric adenocarcinoma is
an ongoing challenge considering the poor prognosis. So
far, the effectiveness of chemotherapy in a preoperative
as well as in a palliative situation has been demonstrated
by several trials [2,24]. The superiority of multidrug regi-
mens over mono-therapies has been proven. Therefore,
great efforts are currently made to enhance the antican-
cer effects of chemotherapy. The integration of molecu-
lar targeted agents into common treatment schedules
may be a promising approach.
In this trial, safety and tolerability of imatinib in com-
bination with 5-FU and platin-based combination
chemotherapy were evaluated to determine the MTD.
Analysis of the toxicity data from treatment of 35
patients in a 3-patient-cohort dose-escalating design
revealed 600 mg imatinib as the MTD. This finding
is similar to the results of the study by Al-Batran
et al., who had examined imatinib combined with 5FU/
leucovorin chemotherapy in gastrointestinal cancers [19].
The observed side effects were moderate and most of the
toxicities observed were related to chemotherapy or pro-
gression of tumor disease. Grade 3 and grade 4 toxicities
Table 4 Toxicities according to the National Cancer Institute Common Toxicity Criteria
Dose level (mg) 1 (300) 2 (400) 3 (500) 4 (600) 5 (700) Total
n 6 3 3 11 2 35
Toxicity grade 1/2 3 4 1/2 3 4 1/2 3 4 1/2 3 4 1/2 3 4 1/2 (%) 3 (%) 4 (%)
Hematologic toxicity
Anemia - - - - 1 - - - - 1 1 - - - - 1 (2,9) 2 (5,7) -
Neutropenia - - - 1 - - 1 - - 1 1 - - - - 3 (8,6) 1(2,9) -
Thrombocytopenia - - - - - - 2 - - 1 - - - - - 3 (8,6) - -
Nonhematologic toxicity
Nausea 5 - - 1 - - 1 - - 10 2 - - - - 17 (48,6) 2 (5,7) -
Vomiting 1 1 - 1 - - - - - 6 - - - - - 8 (22,9) 1(2,9) -
Stomatitis 2 - - - - - - - - 2 - - - - - 4 (11,4) - -
Diarrhea 3 - - - - - - - - 14 - - - - - 17 (48,6) - -
Gastrointestinal perforation - - - - - - - - - - - - - - 2 - - 2 (5,7)
Gastrointestinal bleeding - - - - - - - - - 1 1 - - - - 1(2,9) 1(2,9) -
Constipation 1 1 - - - - - - - 7 - - - - - 8 (22,9) 1(2,9) -
Edema / fluid retention 1 - - - - - 2 1 - 5 - - - - - 8 (22,9) 1(2,9) -
Fatigue - - - 1 - - - - - 10 1 - - - - 11 (31,4) 1(2,9) -
Fever - - - 1 - - - - - 1 - - - - - 2 (5,7) - -
Pain 3 - - - - - 1 - - 3 2 - 1 - - 8 (22,9) 2 (5,7) -
Sensory neuropathy 1 - - - - - - - - 3 - - - - - 4 (11,4) - -
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5-FU and platin-based treatments. Unexpectedly no
grade 3 and 4 diarrhea occurred and only one significant
case of edema or fluid retention was registered.
Two gastric perforations constituted the most serious
events of this trial. Emergency surgery in both patients
provided immediate care and no life-threatening conse-
quences were observed. However, the reasons and
underlying biological mechanisms for the perforations
remain unclear. A particular strong effect on the tumor
tissue at the dosage level of 700 mg imatinib could be
discussed. There are several cases of perforations during
imatinib therapy referred to in the literature, mostly due
to a rapid response of the primary tumor or the metasta-
ses [25]. But in both cases perforation emerged already
after 7 days of imatinib intake and therefore after only
one course of chemotherapy. One patient experienced
perforation 4 weeks after therapy start with repeated
interruptions of treatment as described before. Histo-
pathological analysis of the resected specimens showed
poorly differentiated tumors with transmural infiltration
in both cases which is regarded to be a negative prog-
nostic factor [26]. These findings may argue that the pri-
mary tumors were the reason for the perforations, but
final determination was impossible. In addition,
increased uptake of chemotherapy into the cancer cells
mediated by imatinib could be a further reason for the
observed large impact of the combination treatment on
primary gastric cancer.Regarding activity the combination of imatinib and
chemotherapy did not completely meet the expectations.
Compared with response rates of about 38% under treat-
ment with cisplatin/5-FU/leucovorin reported on in
former studies [27] the results of this trial lag slightly be-
hind. In combination with the observed perforations in
two patients at a very early point of treatment the
observed reduced response rate may indicate that the
combination of chemotherapy with imatinib leads to a
fast and dramatic reduction of cancer cells, however, the
cancer cells ultimately develop resistance mechanisms
early which counteract the observed initial tumor
shrinkage. Nonetheless, this phase I study was designed
to determine the maximal tolerated dose. Considering
the small number of patients assessable for response, no
final conclusions can be made.Conclusions
In summary, the combination of imatinib and cisplatin-
based chemotherapy was well tolerated. A dose of 600 mg
imatinib daily was defined as the maximum tolerated dose
in this trial. Anticancer activity of this combination was
observed transiently and early. Therefore, this treatment
regimen may provide benefit especially in the preopera-
tive setting. However, further investigations – particularly
of a larger group of patients - are required to confirm the
amplification of chemotherapy effects by imatinib in this
and other cancers.
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